This page is intended as reference information for the general public.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
What is Cibinqo used for?
Cibinqo is used to treat adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis, also known as atopic eczema, who are candidates for systemic therapy.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cibinqo please visit the electronic Medicines Compendium (eMC) for Great Britain.
Cibinqo is used to treat adults with moderate-to-severe atopic dermatitis, also known as atopic eczema, who are candidates for systemic therapy.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cibinqo please visit the electronic Medicines Compendium (eMC) for Northern Ireland.
What is Cibinqo?
Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase inhibitors and works by reducing the activity of an enzyme in the body called ‘Janus kinase’, which is involved in inflammation.
Formulation and Classification
Cibinqo is a pink tablet and comes in three different strengths: 200mg, 100mg, 50mg.
The medicine can only be obtained with a prescription.
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. One of the ways they do this is by producing evidence-based guidance. See NICE guidance on Cibinqo (abrocitinib).
The Scottish Medicines Consortium (SMC) is the national source of advice on the clinical and cost-effectiveness of all medicines for NHS Scotland. Their aim is to ensure that people in Scotland have timely access to medicines that provide most benefit based on best available evidence. See SMC guidance on Cibinqo (abrocitinib).
▼ This medicine is subject to additional monitoring.
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.